Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Tumori

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/030089161410000201PMID 24852853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Two‐Sample Dispersion Problem and Other Two‐Sample Problems

  2015cited by this paper
• Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening

  2013cited by this paper
• Circulating DNA and next-generation sequencing.

  2012cited by this paper
• Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

  2012cited by this paper
• Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation

  2012cited by this paper
• Impact of a Population-Based Colorectal Cancer Screening Program on Local Health Services Demand in Italy: A 7-Year Survey in a Northern Province

  2011cited by this paper
• Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy

  2011cited by this paper
• Circulating tumour markers can define patients with normal colons, benign polyps and cancers

  2011cited by this paper
• Circulating tumour markers can define patients with normal colons, benign polyps, and cancers

  2011cited by this paper
• Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers

  2010cited by this paper
• Circulating free tumor DNA and colorectal cancer.

  2010cited by this paper
• Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?

  2010cited by this paper
• Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

  2010cited by this paper
• Cell-Free Nucleic Acids Circulating in the Plasma of Colorectal Cancer Patients Induce the Oncogenic Transformation of Susceptible Cultured Cells

  2010cited by this paper
• Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer.

  2008cited by this paper
• Circulating Cell-Free DNA in Plasma of Locally Advanced Rectal Cancer Patients Undergoing Preoperative Chemoradiation: A Potential Diagnostic Tool for Therapy Monitoring

  2008cited by this paper
• Circulating mutant DNA to assess tumor dynamics

  2008cited by this paper
• Free circulating DNA as possible tumour marker in colorectal cancer.

  2007cited by this paper
• Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer

  2006cited by this paper
• Quantitative Analysis of Plasma DNA in Colorectal Cancer Patients

  2006cited by this paper
• TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.

  2006cited by this paper
• Detection and Quantification of Mutations in the Plasma of Patients With Colorectal Tumors

  2006cited by this paper
• Detection and quantification of mutations in the plasma of patients with colorectal tumors.

  2005cited by this paper
• Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers

  2004cited by this paper
• Quantification of free circulating DNA as a diagnostic marker in lung cancer.

  2003cited by this paper
• O-297 Quantification of free circulating DNA as a diagnostic marker in lung cancer

  2003cited by this paper
• Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.

  2003cited by this paper
• p16INK4A Hypermethylation Detected by Fluorescent Methylation-specific PCR in Plasmas from Non-Small Cell Lung Cancer

  2002cited by this paper
• A Hypermethylation Detected by Fluorescent Methylation-specific PCR in Plasmas from Non-Small Cell Lung Cancer 1

  2002cited by this paper
• p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.

  2002cited by this paper
• About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.

  2001cited by this paper
• Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma

  2001cited by this paper
• Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA.

  2000cited by this paper
• Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells

  1999cited by this paper
• Methods of correcting for multiple testing: operating characteristics.

  1997cited by this paper
• Flexible regression models with cubic splines.

  1989cited by this paper
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper

• Progress in the field of noninvasive diagnostics for colorectal cancer: a systematic review for the accuracy of blood-based biomarkers for detection of advanced pre-cancerous lesions

  2023influential citation
• Liquid biopsy in colorectal cancer: onward and upward.

  2023cites this paper
• The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes.

  2021cites this paper
• Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review

  2021cites this paper
• Detection of KRAS mutations by colon and lung cancer exosomes and analysis of mutational statuses compared to primary tissue

  2021cites this paper
• Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors

  2020cites this paper
• Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge

  2020cites this paper
• Colorectal Adenomas—Genetics and Searching for New Molecular Screening Biomarkers

  2020cites this paper
• Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology

  2020cites this paper
• Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review

  2019cites this paper
• Towards Circulating-Tumor DNA-Based Precision Medicine

  2019cites this paper
• Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.

  2019cites this paper
• Quantitative Methylation-Specific PCR: A Simple Method for Studying Epigenetic Modifications of Cell-Free DNA.

  2019cites this paper
• A Pipeline for ctDNA Detection Following Primary Tumor Profiling Using a Cancer-Related Gene Sequencing Panel.

  2019cites this paper
• Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update

  2019cites this paper
• The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis

  2019cites this paper
• Detection of Tumor-Related Biomarkers in Hepatocellular Carcinoma Patients by Sequencing Circulating Cell-Free DNA

  2019cites this paper
• Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma

  2019cites this paper
• Liquid biopsy in colorectal carcinoma: the search for potential prognostic and predictive biomarkers

  2019cites this paper
• Current Utility and Future Applications of ctDNA in Colorectal Cancer

  2018cites this paper
• Liquid biopsy - emergence of a new era in personalized cancer care

  2018cites this paper
• Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer

  2018cites this paper
• Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.

  2018cites this paper
• Role of circulating tumor DNA in the management of patients with colorectal cancer.

  2018cites this paper
• Assessment of basal-like breast cancer by circulating tumor DNA analysis.

  2018cites this paper
• Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity

  2018cites this paper
• Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review

  2018cites this paper
• Clinical Interest of Circulating Tumor DNA in Oncology.

  2018cites this paper
• The importance of circulating tumor products as „liquid biopsies” in colorectal cancer

  2018cites this paper
• Liquid Biopsy: Golden Era of Personalized Medicine in Oncology

  2018cites this paper
• Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer.

  2017cites this paper
• Liquid Biopsy in Colorectal Cancer

  2017cites this paper
• Tumor‐associated DNA mutation detection in individuals undergoing colonoscopy

  2017cites this paper
• The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review

  2017cites this paper
• Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis

  2017cites this paper
• Mutation detection with a liquid biopsy 96 mutation assay in cancer patients and healthy donors

  2017cites this paper
• Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

  2017cites this paper
• The clinical role of circulating free tumor DNA in gastrointestinal malignancy

  2017cites this paper
• Assessing Circulating Cell-free Tumour DNA as a Potential Biomarker for Early Detection and Chemoprevention of Colorectal Cancer

  2017cites this paper
• KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population

  2017cites this paper
• Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis

  2016cites this paper
• Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

  2016cites this paper
• Role of circulating free DNA in colorectal cancer

  2016cites this paper
• Plasma DNA as a potential biomarker for breast cancer detection

  2016cites this paper
• KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.

  2016cites this paper
• Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer.

  2016cites this paper
• Progress and potential of RAS mutation detection for diagnostics and companion diagnostics

  2016cites this paper
• Epigenetic Biomarkers in Colorectal Cancer

  2016cites this paper
• Blood Tests for Colorectal Cancer Screening in the Standard Risk Population

  2015cites this paper
• Badanie molekularnych markerów wykorzystywanych w leczeniu chorych na raka jelita grubego

  2015cites this paper
• Colorectal cancer screening: current status.

  2014cites this paper
• Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer

  2014cites this paper